Axinn Granted Summary Judgment in Delaware Federal Court
June 24, 2014
Law360
A Delaware federal judge on June 24 granted summary judgment to Axinn client Alvogen in a lawsuit brought by Novartis AG over a generic version of the Exelon dementia treatment patch. After the close of fact discovery, Novartis granted a covenant not to sue to Alvogen.
Click here to read about the judgment in Law360’s article.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
IPWatchdog Sixth Annual Live Conference
Speaking Engagement
Intellectual Property
ABA White Collar Crime Institute 2026
Speaking Engagement
GCR Live Cartels: 2026
Speaking Engagement
Antitrust
SCCE 14th Annual European Compliance & Ethics Institute
Speaking Engagement
Antitrust
Noerr Competition Day 2026
Speaking Engagement
Antitrust
Axinn Antitrust Insight: "New" HSR Form Remains in Effect For Now – Fifth Circuit Temporarily Freezes District Court Order that Vacated the New HSR Rule
Axinn Viewpoints
Antitrust
Consumer Brands CPG Legal Forum 2026
Speaking Engagement
NBA CLS 39th Annual Corporate Counsel Conference
Sponsorship
Antitrust
University of Pennsylvania Journal of Business Law Annual Symposium 2026
Speaking Engagement
Antitrust
Chambers Recognizes Axinn’s Antitrust Practice in 2026 Global Rankings — With New Recognition in Cartel Category
Awards & Recognitions
Antitrust
